Anti-androgen therapy in non-metastatic castration-resistant prostate cancer

摘要

Among men with non-metastatic, castration-resistant prostate cancer (CRPC) with rapidly rising prostate-specific antigen (PSA) levels, enzaluta-mide (XTANDI?; Astellas Pharma US, Inc.) treatment led to a clinically meaningful and significant 71% lower risk of metastasis or death versus placebo. The results of the double-blind, phase 3, PROSPER clinical trial that investigated the efficacy of enzalutamide for non-metastatic CRPC were recently reported in The New England Journal of Medicine [1], and led to approval of enzalutamide by the US Food and Drug Administration (FDA).